Transmucosal and subcutaneous compositions
The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d 2 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d 4 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.
1. A transmucosal pharmaceutical formulation comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (Compound of Formula I) in free base, co-crystal or salt form, or comprising 1-(4-fluoro-phenyl)-4-(6bR,10aS)-2,2-d 2 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (Compound of Formula II) in free base, co-crystal or salt form, or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d 4 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (Compound of Formula III) in free base, co-crystal or salt form;
wherein the formulation is a rapidly dissolving tablet or wafer, a sublingual tablet or wafer, a rapidly dissolving film, sublingual film, buccal film, oral gel, or a rapidly dissolving sublingual or buccal gel.
2. The formulation of claim 1 , wherein the formulation comprises the Compound of Formula I or the Compound of Formula II or the Compound of Formula III in free base form.
3. The formulation of claim 1 , wherein the formulation comprises the Compound of Formula I or the Compound of Formula II or the Compound of Formula III in salt form.
4. The formulation of claim 3 , wherein the salt form is tosylate.
5. The formulation of claim 1 , wherein the formulation comprises from 0.01 to 10 mg of the Compound of Formula I (free base equivalent) or the Compound of Formula II (free base equivalent) or the Compound of Formula III (free base equivalent).
6. The formulation of claim 1 , further comprising one or more hydrophilic water-soluble or water swellable polymers.
7. The formulation of claim 6 , wherein the polymer is selected from the group consisting of natural or modified cellulosic polymers, polymers of ethylene oxide and/or propylene oxide, polymers comprising acrylic acid monomers, natural or modified gums, natural or modified starches, or any mixture thereof.
8. The formulation of claim 1 , further comprising one or more excipients selected from the group consisting of plasticizers, surfactants, drying agents, flavors, sweeteners, binders, disintegrants, humectants, wetting agents, antioxidants, buffering agents, and thickening agents.
9. The formulation of claim 1 , wherein the formulation is a rapidly dissolving tablet or wafer, or a sublingual tablet or wafer.
10. The formulation of claim 1 , wherein the formulation is an oral spray, or a sublingual spray or buccal spray.
11. The formulation of claim 1 , wherein the formulation is a rapidly dissolving film or a sublingual film or buccal film.
12. The formulation of claim 11 , wherein the film has uniform or substantially uniform thickness.
13. The formulation of claim 11 , wherein the Compound of Formula I or II or III is uniformly or substantially uniformly distributed throughout the film.
14. The formulation of claim 1 , wherein the formulation is an intranasal spray.
15. The formulation of claim 1 , wherein the formulation is an oral gel or a rapidly dissolving sublingual or buccal gel.
16. The formulation of claim 1 , wherein the formulation is an intravaginal formulation, or an intravaginal rapidly dissolving tablet, wafer or gel, or an intravaginal spray or an intravaginal rapidly dissolving film.
17. The formulation of claim 1 , wherein the Compound of Formula I or the Compound of Formula II or the Compound of Formula III is incorporated into the formulation as microparticles.
18. The formulation of claim 1 , wherein the Compound of Formula I or the Compound of Formula II or the Compound of Formula III is incorporated into the formulation as nanoparticles.
19. The formulation of claim 1 , wherein the formulation is absorbed by the mucosa or dissolves in less than 30 seconds after administration.
20. A subcutaneous pharmaceutical formulation comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (Compound of Formula I) in free base, co-crystal or salt form, or comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d 2 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (Compound of Formula II) in free base, co-crystal or salt form, or comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d 4 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (Compound of Formula III) in free base, co-crystal or salt form.
21. The formulation of claim 1 , wherein the formulation comprises the Compound of Formula I in tosylate salt form.
22. The formulation of claim 9 , wherein the formulation comprises the Compound of Formula I in tosylate salt form.
23. The formulation of claim 11 , wherein the formulation comprises the Compound of Formula I in tosylate salt form.
24. The formulation of claim 20 , wherein the formulation comprises the Compound of Formula I in tosylate salt form.